Et in vivo interaktionsstudie med warfarin indikerede, at rosiglitazon ikke interagerer med CYP2C9- substrater in vivo.
An in vivo interaction study with warfarin indicated that rosiglitazone does not interact with CYP2C9 substrates in vivo.